Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ADMA Biologics, covering investors who purchased shares between August 9, 2024, and March 25, 2026, highlighting significant transparency issues during this period.
- Allegations: The lawsuit alleges that ADMA Biologics engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls, leading to materially misleading positive statements about the company's business and operations, which undermined investor confidence.
- Stock Price Impact: Following a report from Culper Research on March 24, 2026, ADMA Biologics' stock price plummeted by 29.1% over two trading days, from $13.59 to $9.63, reflecting market concerns regarding the company's financial health.
- Investor Actions: ADMA investors have until August 10, 2026, to apply for lead plaintiff status in the class action, representing other investors and emphasizing the importance of corporate governance and financial transparency.
See More
Investor Class Action Lawsuit Reminder
- Via Transportation Class Action: A class action lawsuit against Via Transportation, Inc. (NYSE:VIA) alleges that from September 2025 to June 2026, the company failed to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Legal Risks: Zillow Group, Inc. (NASDAQ:Z,ZG) faces a class action lawsuit for the period from February 2025 to May 2026, accused of misrepresenting its agreement with Redfin as a partnership rather than an acquisition, and downplaying legal exposure amid antitrust scrutiny, requiring investor action by August 10, 2026.
- ADMA Biologics Issues: ADMA Biologics, Inc. (NASDAQ:ADMA) is implicated in a class action from August 2024 to March 2026 for failing to disclose related party transactions and revenue inflation tactics, lacking adequate internal controls, misleading investors about its operations, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors that participation in these class actions does not require immediate action, allowing investors to retain counsel of their choice or remain absent while ensuring their rights are protected.
See More
Reminder of Class Action Lawsuit for ADMA Biologics Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics is August 10, 2026, for those who purchased securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in channel stuffing to artificially inflate revenue and failed to disclose related party transactions, misleading investors about the company's operations.
- Stock Price Impact: Following the report, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which significantly harmed investors' financial interests.
- Legal Implications: The lawsuit claims that ADMA made materially false statements throughout the class period and failed to disclose adverse facts about its business and prospects, potentially leading to greater financial losses for investors.
See More
ADMA Biologics Accused of Concealing Financial Risks
- Disclosure Controversy: ADMA Biologics allegedly used vague risk language in seven SEC filings from August 2024 to March 2026, claiming its internal controls could not provide absolute assurance, thereby obscuring the fictitious nature of its reported 20% ASCENIV revenue growth, which was actually a 3% decline driven by channel stuffing.
- Related Party Transaction Issues: The company disclosed related party transactions with GenesisBPS, owned by the Grossman family, reporting amounts ranging from $34,000 to $400,000 per period, yet the repetitive nature of these disclosures failed to reveal their significant impact on financial health, potentially misleading investors about the company's true financial status.
- Legal Liability Risks: The lawsuit highlights that ADMA's generic risk warnings do not shield it from liability when specific issues are already occurring, as investors are entitled to know about related party sales and their impact on revenue growth, which could expose the company to severe legal consequences.
- Investor Action Recommendations: Affected investors are advised to gather purchase records and contact SueWallSt for a free evaluation to ensure they can participate in claims and recover losses incurred due to ADMA's alleged disclosure failures before the lead plaintiff deadline of August 10, 2026.
See More
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ADMA Biologics, covering investors who purchased shares between August 9, 2024, and March 25, 2026, highlighting significant transparency issues during this period.
- Allegations: The lawsuit alleges that ADMA Biologics engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls, leading to materially misleading positive statements about the company's business and operations, which undermined investor confidence.
- Stock Price Impact: Following a report from Culper Research on March 24, 2026, ADMA Biologics' stock price plummeted by 29.1% over two trading days, from $13.59 to $9.63, reflecting market concerns regarding the company's financial health.
- Investor Actions: ADMA investors have until August 10, 2026, to apply for lead plaintiff status in the class action, representing other investors and emphasizing the importance of corporate governance and financial transparency.
See More
Investor Class Action Lawsuit Reminder
- Via Transportation Class Action: A class action lawsuit against Via Transportation, Inc. (NYSE:VIA) alleges that from September 2025 to June 2026, the company failed to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Legal Risks: Zillow Group, Inc. (NASDAQ:Z,ZG) faces a class action lawsuit for the period from February 2025 to May 2026, accused of misrepresenting its agreement with Redfin as a partnership rather than an acquisition, and downplaying legal exposure amid antitrust scrutiny, requiring investor action by August 10, 2026.
- ADMA Biologics Issues: ADMA Biologics, Inc. (NASDAQ:ADMA) is implicated in a class action from August 2024 to March 2026 for failing to disclose related party transactions and revenue inflation tactics, lacking adequate internal controls, misleading investors about its operations, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors that participation in these class actions does not require immediate action, allowing investors to retain counsel of their choice or remain absent while ensuring their rights are protected.
See More
Reminder of Class Action Lawsuit for ADMA Biologics Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics is August 10, 2026, for those who purchased securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in channel stuffing to artificially inflate revenue and failed to disclose related party transactions, misleading investors about the company's operations.
- Stock Price Impact: Following the report, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which significantly harmed investors' financial interests.
- Legal Implications: The lawsuit claims that ADMA made materially false statements throughout the class period and failed to disclose adverse facts about its business and prospects, potentially leading to greater financial losses for investors.
See More
ADMA Biologics Accused of Concealing Financial Risks
- Disclosure Controversy: ADMA Biologics allegedly used vague risk language in seven SEC filings from August 2024 to March 2026, claiming its internal controls could not provide absolute assurance, thereby obscuring the fictitious nature of its reported 20% ASCENIV revenue growth, which was actually a 3% decline driven by channel stuffing.
- Related Party Transaction Issues: The company disclosed related party transactions with GenesisBPS, owned by the Grossman family, reporting amounts ranging from $34,000 to $400,000 per period, yet the repetitive nature of these disclosures failed to reveal their significant impact on financial health, potentially misleading investors about the company's true financial status.
- Legal Liability Risks: The lawsuit highlights that ADMA's generic risk warnings do not shield it from liability when specific issues are already occurring, as investors are entitled to know about related party sales and their impact on revenue growth, which could expose the company to severe legal consequences.
- Investor Action Recommendations: Affected investors are advised to gather purchase records and contact SueWallSt for a free evaluation to ensure they can participate in claims and recover losses incurred due to ADMA's alleged disclosure failures before the lead plaintiff deadline of August 10, 2026.
See More
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
